Document is current

Any future updates will be listed below

Correction to: Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable pi‑based therapy in relapsed/refractory multiple myeloma

Crossref DOI link: https://doi.org/10.1007/s00277-023-05355-7

Published Online: 2023-07-11

Published Print: 2023-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark